Contribution of ParC -and GyrA- Mutations to Fluoroquinolone Treatment Failures in Mycoplasma genitalium : A Systematized Review
Abstract
While macrolide resistance in Mycoplasma genitalium is consistently associated with mutations in the 23S rRNA gene, enabling macrolide resistance-guided therapies, the correlation between genotype and fluoroquinolone resistance is less definitive. We aim to estimate the contribution of ParC and GyrA mutations in M. genitalium to fluoroquinolone resistance through a systematized review of the scientific literature. In May 2025, a Boolean search was performed in PubMed for manuscripts reporting fourth-generation fluoroquinolone-based treatment outcomes in M. genitalium infections harboring ParC mutations at S83 and/or D87. Concurrent GyrA mutations were also recorded. Sixteen studies were included in the review, accounting for 376 M. genitalium infections. Most treatment failures were associated with the S83I variant in ParC, where 43% of cases receiving fluoroquinolones failed. While the rate of treatment failure estimated among S83R variants was slightly higher (50%), this mutation was much less frequently identified. On the other hand, no treatment failures were identified associated with mutations S83N, D87G, and D87H. Concomitant GyrA mutation M95I or variations affecting D99 significantly increased the rate of treatment failure up to 3-fold. Sitafloxacin was significantly more effective than moxifloxacin in the presence of resistance mutations. This descriptive review provides compiled and preliminary data regarding the contribution of parC and gyrA mutations to…
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.